Celgene (BUE:CELG) LT-Debt-to-Total-Asset: 0.44 (As of Sep. 2019)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Celgene LT-Debt-to-Total-Asset?

Celgene BUE:CELG 10 LT-Debt-to-Total-Asset is 0.44 as of Sep. 2019. GuruFocus rates BUE:CELG with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Celgene's long-term debt to total assests ratio for the quarter that ended in Sep. 2019 was 0.44.

Celgene's long-term debt to total assets ratio declined from Sep. 2018 (0.58) to Sep. 2019 (0.44). It may suggest that Celgene is progressively becoming less dependent on debt to grow their business.

Celgene  (BUE:CELG) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Celgene LT-Debt-to-Total-Asset Related Terms

Celgene LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Celgene's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celgene LT-Debt-to-Total-Asset Chart

Celgene Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.53 0.49 0.53 0.56

Celgene Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.56 0.53 0.51 0.44

Celgene LT-Debt-to-Total-Asset Calculation

Celgene's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2018 is calculated as

LT Debt to Total Assets (A: Dec. 2018 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2018 )/Total Assets (A: Dec. 2018 )
=745390.184/1337773.469
=0.56

Celgene's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2019 is calculated as

LT Debt to Total Assets (Q: Sep. 2019 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2019 )/Total Assets (Q: Sep. 2019 )
=1022830.598/2313267.102
=0.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.44 mean?
Celgene (BUE:CELG) has a LT-Debt-to-Total-Asset of 0.44 as of Sep. 2019. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Celgene and its competitors.
Is Celgene's LT-Debt-to-Total-Asset too high?
Celgene's current LT-Debt-to-Total-Asset is 0.44. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's LT-Debt-to-Total-Asset compare to GILD and BIIB?
Celgene's LT-Debt-to-Total-Asset of 0.44 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Celgene and its competitors. Celgene's current LT-Debt-to-Total-Asset is 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current LT-Debt-to-Total-Asset of 0.44. The current LT-Debt-to-Total-Asset is 0.44. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Celgene (BUE:CELG), the current LT-Debt-to-Total-Asset is 0.44 as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celgene Business Description

Address 86 Morris Avenue, Summit, NJ, USA, 07901
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.